Literature DB >> 1380037

Oncostatin M is a differentiation factor for myeloid leukemia cells.

A G Bruce1, I H Hoggatt, T M Rose.   

Abstract

Oncostatin M (OSM) is a 28-kDa glycoprotein produced by stimulated macrophages and T lymphocytes that inhibits the proliferation of a number of different cell lines derived from solid tumors. Analysis of both amino acid sequence and gene structure has demonstrated that OSM is a member of a cytokine family that includes leukemia inhibitory factor (LIF), IL-6, and granulocyte colony-stimulating factor (G-CSF). We demonstrate that, like LIF, IL-6 and G-CSF, OSM can induce the differentiation of the myeloblastic M1 murine leukemia cells into macrophage-like cells. The morphologic and functional changes induced by OSM are more similar to those observed with LIF and IL-6 than those induced with G-CSF. OSM can also induce the differentiation of the histiocytic U937 human leukemia cells in the presence of granulocyte-macrophage CSF, a property shared with LIF and IL-6. In murine M1 cells, binding of labeled OSM is completely inhibited by excess LIF or OSM, reflecting the binding of OSM to the high affinity form of the murine LIF receptor. In contrast, the binding of labeled OSM to human U937 leukemia cells is inhibited by OSM, but the inhibition by LIF is significantly less. These results suggest that, in human leukemia cells, OSM may act through the LIF receptor and an OSM-specific receptor. The existence of an OSM-specific receptor was confirmed by both growth inhibition and competition binding assays on A375 human melanoma cells. The growth of human A375 cells was inhibited by OSM and IL-6 but not LIF or G-CSF. Neither LIF, G-CSF, nor IL-6 could compete with the binding of labeled OSM to A375 cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380037

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Oncostatin m maintains the hematopoietic microenvironment and retains hematopoietic progenitors in the bone marrow.

Authors:  Ken-ichi Minehata; Masaki Takeuchi; Yoko Hirabayashi; Tohru Inoue; Peter J Donovan; Minoru Tanaka; Atsushi Miyajima
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

2.  Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer.

Authors:  A Kamiya; T Kinoshita; Y Ito; T Matsui; Y Morikawa; E Senba; K Nakashima; T Taga; K Yoshida; T Kishimoto; A Miyajima
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

3.  Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.

Authors:  C Toniatti; A Cabibbo; E Sporena; A L Salvati; M Cerretani; S Serafini; A Lahm; R Cortese; G Ciliberto
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

4.  Neuropoietic cytokines and activin A differentially regulate the phenotype of cultured sympathetic neurons.

Authors:  M J Fann; P H Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

5.  Resonance assignments for Oncostatin M, a 24-kDa alpha-helical protein.

Authors:  R C Hoffman; F J Moy; V Price; J Richardson; D Kaubisch; E A Frieden; J D Krakover; B J Castner; J King; C J March; R Powers
Journal:  J Biomol NMR       Date:  1996-06       Impact factor: 2.835

6.  Colony-stimulating factor-1 (CSF-1) receptor-mediated macrophage differentiation in myeloid cells: a role for tyrosine 559-dependent protein phosphatase 2A (PP2A) activity.

Authors:  K A McMahon; N J Wilson; D C Marks; T L Beecroft; G A Whitty; J A Hamilton; X F Csar
Journal:  Biochem J       Date:  2001-09-01       Impact factor: 3.857

7.  Oncostatin M regulates membrane traffic and stimulates bile canalicular membrane biogenesis in HepG2 cells.

Authors:  Johanna M van der Wouden; Sven C D van IJzendoorn; Dick Hoekstra
Journal:  EMBO J       Date:  2002-12-02       Impact factor: 11.598

8.  The SCL gene product is regulated by and differentially regulates cytokine responses during myeloid leukemic cell differentiation.

Authors:  T Tanigawa; N Elwood; D Metcalf; D Cary; E DeLuca; N A Nicola; C G Begley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

9.  A dual role for oncostatin M signaling in the differentiation and death of mammary epithelial cells in vivo.

Authors:  Paul G Tiffen; Nader Omidvar; Nuria Marquez-Almuina; Dawn Croston; Christine J Watson; Richard W E Clarkson
Journal:  Mol Endocrinol       Date:  2008-10-16

10.  A novel 110 kDa form of myosin XVIIIA (MysPDZ) is tyrosine-phosphorylated after colony-stimulating factor-1 receptor signalling.

Authors:  Maddalena Cross; Xavier F Csar; Nicholas J Wilson; Gaël Manes; Theresa A Addona; Denese C Marks; Genevieve A Whitty; Keith Ashman; John A Hamilton
Journal:  Biochem J       Date:  2004-05-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.